

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  David Botstein et al.  Serial No.: Not Yet Assigned  Filed: Herewith  For: SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	Group Art Unit: Not Yet Assigned  Examiner: Not Yet Assigned  Express Mail Label No.: EL 889 331 008 US December 27, 2001
--	--

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Prior to substantive examination of the above captioned patent application (which is filed herewith), and for calculation of the proper filing fee, Applicants respectfully request that the following amendments be entered.

**In the Specification:**

Please insert the following new paragraph at page 1, line 2:

**--RELATED APPLICATIONS**

This is a continuation application claiming priority under 35 USC §120 to US serial number 09/866,034 filed 5/25/01 which claims priority under 35 USC §120 to PCT international application numbers: PCT/US99/12252, filed June 2, 1999; PCT/US99/28634, filed December 1, 1999; PCT/US99/28551, filed December 2, 1999; PCT/US00/03565, February 11, 2000; PCT/US00/04414, filed February 22, 2000; PCT/US00/05841, filed March 2, 2000; PCT/US00/08439, filed March 30, 2000; PCT/US00/14941, filed May 30, 2000; PCT/US00/15264, filed June 2, 2000; PCT/US00/32678, filed December 1, 2000; and which claims priority under 35 USC § 119 to US provisional application numbers: 60/095,325, filed August 4, 1998; 60/112,851, filed December 16, 1998; 60/113,145, filed December 16, 1998; 60/113,511, filed December 22, 1998; 60/115,558, filed January 12, 1999; 60/115,565, filed January 12, 1999; 60/115,733, filed January 12, 1999; 60/119,341, filed February 9, 1999; 60/119,537, filed February 10, 1999; 60/119,965, filed

February 12, 1999;60/162,506, filed October 29, 1999;60/170,262, filed December 9, 1999;60/187,202, filed March 3, 2000, the entire disclosures of which are hereby incorporated by reference.--

**In the Claims:**

Please cancel Claims 1-21 without prejudice or disclaimer.

Please add new Claims 22-34 as follows.

--22. (New) An isolated polypeptide having at least 80% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (b) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9),

lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203583.

23. (New) The isolated polypeptide of Claim 22 having at least 85% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (b) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9),

lacking its associated signal peptide;

(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9);

(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide; or

(e) the amino acid sequence of the polypeptide encoded by the full-length coding

sequence of the cDNA deposited under ATCC accession number 203583.

24. (New) The isolated polypeptide of Claim 22 having at least 90% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (b) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203583.

25. (New) The isolated polypeptide of Claim 22 having at least 95% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (b) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203583.

26. (New) The isolated polypeptide of Claim 22 having at least 99% amino acid sequence identity to:

- (a) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (b) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203583.

27. (New) An isolated polypeptide comprising:

- (a) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (b) the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide;
- (c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9);
- (d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide; or
- (e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203583.

28. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 6 (SEQ ID NO:9).

29. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of

the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide.

30. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9).

31. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 6 (SEQ ID NO:9), lacking its associated signal peptide.

32. (New) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203583.

33. (New) A chimeric polypeptide comprising a polypeptide according to Claim 22 fused to a heterologous polypeptide.

34. (New) The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.--

**REMARKS**

Claims 1-21 have been cancelled. New Claims 22-34 have been added. Applicants respectfully request early entry of these new claims for prosecution in this application. The Examiner is invited to contact the undersigned at (650)225-4563 if any issues may be resolved in that manner.

Attached hereto is a marked-up version of the changes made to the and by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Respectfully submitted,  
GENENTECH, INC.

Date: December 27, 2001

By: Elizabeth M. Barnes  
Elizabeth M. Barnes  
Reg. No. 35,059  
Telephone: (650) 225-4563



09157

PATENT TRADEMARK OFFICE

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the specification:**

A new paragraph beginning at page 1, line 2 has been added.

**In the claims:**

Claims 1-21 have been cancelled.

Claims 22-34 have been added.